Compass Pathways plc CMPS on Wednesday shared topline 52-week Part C results from its Phase 3 COMP005 study evaluating ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in ...
Compass Pathways has selected five U.S. organizations to receive grants for developing healthcare provider training programs ...
ATLANTA--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the ...
Compass said patients who received an additional 25 mg dose of COMP360 saw their depression scores improve by an average of ...
CMPS is testing a breakout after positive Phase 3 data, with a close above $15.40 potentially opening the way toward ...
The precipitous fall occurred on Monday, 06/23/2025 when the stock dropped from its close at $4.63 on the previous Friday to open Monday at $3.08. It hit an interday low of $2.25, closing the hectic ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at Psych Congress ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...